PSS16 - COST PER RESPONDER ANALYSIS OF CALCIPOTRIOL PLUS BETAMETHASONE DIPROPIONATE AEROSOL FOAM VERSUS NON-BIOLOGIC SYSTEMIC THERAPY IN THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS

Value in Health ◽

10.1016/j.jval.2018.09.2516 ◽

2018 ◽

Vol 21 ◽

pp. S425

Author(s):

L. Becla ◽

J.M. Carrascosa ◽

J.F. Antunes ◽

A.P. Bewley ◽

M. Delgado Perala ◽

...

Keyword(s):

Plaque Psoriasis ◽

Systemic Therapy ◽

Betamethasone Dipropionate ◽

Severe Plaque Psoriasis ◽

Responder Analysis ◽

Cost Per Responder

Download Full-text

PSY12 COST PER RESPONDER ANALYSIS OF GUSELKUMAB VERSUS SECUKINUMAB IN THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS BASED ON THE ECLIPSE TRIAL

Value in Health ◽

10.1016/j.jval.2019.09.2640 ◽

2019 ◽

Vol 22 ◽

pp. S903 ◽

Cited By ~ 1

Author(s):

C. Druchok ◽

A.N. Pepper ◽

J. Garside ◽

F. Hassan

Keyword(s):

Plaque Psoriasis ◽

Severe Plaque Psoriasis ◽

Responder Analysis ◽

Cost Per Responder

Download Full-text

PSS17 - COST PER RESPONDER ANALYSIS OF BRODALUMAB COMPARED WITH USTEKINUMAB IN THE TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS IN CANADA

Value in Health ◽

10.1016/j.jval.2018.09.2517 ◽

2018 ◽

Vol 21 ◽

pp. S425

Author(s):

J. Schembri ◽

M. Barbeau ◽

V. Gaudet

Keyword(s):

Plaque Psoriasis ◽

Severe Plaque Psoriasis ◽

Responder Analysis ◽

Cost Per Responder

Download Full-text

Re: Wu JJ, Hansen JB, Patel DS, et al. Effectiveness comparison and incremental cost-per-responder analysis of calcipotriene 0.005%/betamethasone dipropionate 0.064% foam vs. halobetasol 0.01%/tazarotene 0.045% lotion for plaque psoriasis: a matching-adjusted indirect comparative analysis. J Med Econ. 2020;23(6):641–649

Journal of Medical Economics ◽

10.1080/13696998.2020.1835305 ◽

2020 ◽

pp. 1-2

Author(s):

Brad Glick ◽

Annie Guerin ◽

Rajeev Ayyagari ◽

Tina Lin ◽

Abby Jacobson ◽

...

Keyword(s):

Comparative Analysis ◽

Incremental Cost ◽

Plaque Psoriasis ◽

Betamethasone Dipropionate ◽

Responder Analysis ◽

Cost Per Responder

Download Full-text

Cost-per-responder analysis of guselkumab versus secukinumab with the use of efficacy results from pivotal clinical trials in patients with moderate to severe plaque psoriasis

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2018.05.385 ◽

2018 ◽

Vol 79 (3) ◽

pp. AB89

Keyword(s):

Clinical Trials ◽

Plaque Psoriasis ◽

Severe Plaque Psoriasis ◽

Responder Analysis ◽

Cost Per Responder

Download Full-text

Cost per responder analysis of guselkumab versus targeted therapies in the treatment of moderate to severe plaque psoriasis in Germany

Journal of Dermatological Treatment ◽

10.1080/09546634.2020.1793891 ◽

2020 ◽

pp. 1-7

Author(s):

Matthias Augustin ◽

Daniel Wirth ◽

Jörg Mahlich ◽

Alicia N. Pepper ◽

Cheryl Druchok

Keyword(s):

Plaque Psoriasis ◽

Targeted Therapies ◽

Severe Plaque Psoriasis ◽

Responder Analysis ◽

Cost Per Responder

Download Full-text

Cost Per Responder Analysis of Guselkumab versus Adalimumab using Efficacy Results fromm a Head-to-Head Clinical Trial in Patients with Moderate to Severe Plaque Psoriasis

SKIN The Journal of Cutaneous Medicine ◽

10.25251/skin.1.supp.5 ◽

2017 ◽

Vol 1 ◽

pp. s6 ◽

Cited By ~ 1

Author(s):

A Teeple ◽

E Muser

Keyword(s):

Clinical Trial ◽

Plaque Psoriasis ◽

Severe Plaque Psoriasis ◽

Responder Analysis ◽

Cost Per Responder

Abstract Not Available

Download Full-text

Reply: Re: Wu JJ, Hansen JB, Patel DS, et al. Effectiveness comparison and incremental cost-per-responder analysis of calcipotriene 0.005%/betamethasone dipropionate 0.064% foam vs. halobetasol 0.01%/tazarotene 0.045% lotion for plaque psoriasis: a matching-adjusted indirect comparative analysis. J Med Econ. 2020;23(6):641–649

Journal of Medical Economics ◽

10.1080/13696998.2020.1835857 ◽

2020 ◽

pp. 1-2

Author(s):

Jashin J. Wu ◽

Jes B. Hansen ◽

Dharm S. Patel ◽

Nanna Nyholm ◽

Karen A. Veverka ◽

...

Keyword(s):

Comparative Analysis ◽

Incremental Cost ◽

Plaque Psoriasis ◽

Betamethasone Dipropionate ◽

Responder Analysis ◽

Cost Per Responder

Download Full-text

Cost per Responder Analysis of Guselkumab Versus Certolizumab Pegol Using Efficacy Results from Pivotal Clinical Trials in Patients with Moderate to Severe Plaque Psoriasis

SKIN The Journal of Cutaneous Medicine ◽

10.25251/skin.2.supp.81 ◽

2018 ◽

Vol 2 ◽

pp. S80

Author(s):

A Teeple ◽

E Muser

Keyword(s):

Clinical Trials ◽

Plaque Psoriasis ◽

Certolizumab Pegol ◽

Severe Plaque Psoriasis ◽

Responder Analysis ◽

Cost Per Responder

Download Full-text

PBI6 EVALUATION OF BIOLOGIC THERAPIES FOR THE TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS IN COLOMBIA: A COST PER RESPONDER ANALYSIS (CPR)

Value in Health Regional Issues ◽

10.1016/j.vhri.2019.08.062 ◽

2019 ◽

Vol 19 ◽

pp. S12

Author(s):

Y. Gil-Rojas ◽

F. Hernández ◽

G. Romano ◽

P. Lasalvia ◽

C. Castañeda-Cardona ◽

...

Keyword(s):

Plaque Psoriasis ◽

Biologic Therapies ◽

Severe Plaque Psoriasis ◽

Responder Analysis ◽

Cost Per Responder

Download Full-text

Cost per responder analysis of ustekinumab and etanercept for moderate to severe plaque psoriasis

Journal of Dermatological Treatment ◽

10.3109/09546634.2010.542800 ◽

2011 ◽

Vol 22 (3) ◽

pp. 138-143 ◽

Cited By ~ 17

Author(s):

Silas Martin ◽

Steven R. Feldman ◽

Matthias Augustin ◽

Philippe Szapary ◽

Brad Schenkel

Keyword(s):

Plaque Psoriasis ◽

Severe Plaque Psoriasis ◽

Responder Analysis ◽

Cost Per Responder

Download Full-text